OncoMatch/Clinical Trials/NCT07073833
The Safety, Tolerability, and Efficacy of IBR900 Cell Injection in Relapsed/Refractory B-cell Non Hodgkin Lymphoma
Is NCT07073833 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including IBR900 cell and rituximab for relapsed/refractory b-cell non-hodgkin lymphoma.
Treatment: IBR900 cell · rituximab — This is an open label clinical study: Phase Ia is a dose escalation phase, evaluating the safety, tolerability, RP2D, PK characteristics, and preliminary efficacy of IBR900 cell injection in the treatment of relapsed/refractory B-cell non Hodgkin lymphoma (NHL); Phase Ib is the dose expansion stage, which is divided into two parts: monotherapy expansion (queue 1) and combination expansion (queue 2). The monotherapy expansion part evaluates the safety, tolerability, and preliminary efficacy of IBR900 cell injection in the treatment of relapsed/refractory CD20 positive B-cell non Hodgkin lymphoma, while the combination expansion part evaluates the safety, tolerability, and preliminary efficacy of IBR900 cell injection combined with CD20 monoclonal antibodies in the treatment of relapsed/refractory CD20 positive B-cell non Hodgkin lymphoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: MS4A1 positive (CD20 positive)
CD20 positive B-cell non Hodgkin's lymphoma
Allowed: MYC rearrangement
high-grade B-cell lymphoma with MYC and BCL2 rearrangements, high-grade B-cell lymphoma with MYC/BCL2/BCL6 rearrangements
Allowed: BCL2 rearrangement
high-grade B-cell lymphoma with MYC and BCL2 rearrangements, high-grade B-cell lymphoma with MYC/BCL2/BCL6 rearrangements
Allowed: BCL6 rearrangement
high-grade B-cell lymphoma with MYC/BCL2/BCL6 rearrangements
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: anthracycline
previous treatment of anthracycline containing drugs
Must have received: CD20-targeted therapy (rituximab)
previous treatment of rituximab or other CD20 targeted therapies
Must have received: anti-CD20 monoclonal antibody
At least one regimen contains anti-CD20 monoclonal antibody monotherapy or combination therapy
Cannot have received: allogeneic hematopoietic stem cell transplantation
Patients who have received allogeneic hematopoietic stem cell transplantation
Cannot have received: other organ transplantation
other organ transplantation
Cannot have received: autologous hematopoietic stem cell transplantation
Exception: within 100 days before the first dose
autologous hematopoietic stem cell transplantation within 100 days before the first dose
Lab requirements
Cardiac function
LVEF ≤ 55%; NYHA Grade II or above congestive heart failure or active heart disease; Serious arrhythmias that require treatment (excluding atrial fibrillation and paroxysmal supraventricular tachycardia that have been determined by the researchers to have no impact on the trial); QTc interval ≥ 450ms for males and ≥ 470ms for females; Within 6 months prior to administration, there has been a myocardial infarction or bypass or stent surgery; Other heart diseases deemed unsuitable for inclusion by researchers
The patient's heart meets any of the following conditions: left ventricular ejection fraction (LVEF) ≤ 55%; New York Heart Association (NYHA) Grade II or above congestive heart failure or active heart disease; Serious arrhythmias that require treatment (excluding atrial fibrillation and paroxysmal supraventricular tachycardia that have been determined by the researchers to have no impact on the trial); QTc interval ≥ 450ms for males and ≥ 470ms for females; Within 6 months prior to administration, there has been a myocardial infarction or bypass or stent surgery; Other heart diseases deemed unsuitable for inclusion by researchers
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify